Weight Loss and Safety of Semaglutide in Korean Adults Living With Obesity
Follows adults in Korea with obesity who are prescribed semaglutide by their doctors.
Plain-language title generated from the registry record
Registry title: WEgovy Real World Assessment of Weight Loss in Korea
Key facts
- Where
- Busan, Daegu, Daejeon, Goyang-si, Gwangmyeong-si, Gyeonggi-do, Seongnam-si, Seongnam-si, Gyeonggi-do, Seoul, Suwon, Uijeongbu-si, Uijeongbu-si, Gyeonggi-do, Yangsan, and Yongin-si, South KoreaSee the 18 sites
Where in South Korea
- Dong-A University HospitalBusan, South KoreaNo longer taking part
- Inje University Haeundae Paik HospitalBusan, South KoreaNo longer taking part
- Keimyung University Dongsan HospitalDaegu, South KoreaNo longer taking part
- Daejeon Endo Internal Medicine ClinicDaejeon, South KoreaNo longer taking part
- Konyang University HospitalDaejeon, South KoreaNo longer taking part
- National Health Insurance Corporation Ilsan HospitalGoyang-si, South KoreaNo longer taking part
- Chung-Ang University Gwangmyeong HospitalGwangmyeong-si, Gyeonggi-do, South KoreaNo longer taking part
- Seoul National University Bundang HospitalSeongnam-si, South KoreaNo longer taking part
- CHA Bundang Medical CenterSeongnam-si, Gyeonggi-do, South KoreaNo longer taking part
- Seoul Happiness Clinic of internal medicineSeongnam-si, Gyeonggi-do, South KoreaNo longer taking part
- Chung ang University HospitalSeoul, South KoreaNo longer taking part
- Ewha Womans University Seoul HospitalSeoul, South KoreaNo longer taking part
- Korea University Guro HospitalSeoul, South KoreaNo longer taking part
- Ajou University HospitalSuwon, South KoreaNo longer taking part
- The Catholic University of Korea Uijeongbu St. Mary's HospitalUijeongbu-si, South KoreaNo longer taking part
- Uijeongbu Eulji university HospitalUijeongbu-si, Gyeonggi-do, South KoreaNo longer taking part
- Pusan National University Yangsan HospitalYangsan, South KoreaNo longer taking part
- Yongin Severance HospitalYongin-si, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07280221
- Record updated
- 30 September 2026
- Original description
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.Read full original descriptionShow less
WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
Inclusion: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol); The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study; Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label; Male or female, aged ≥ 19 years at the time of signing the informed consent.
Exclusion: Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study; Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice); Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.